Hikma Pharmaceuticals (HIK) Stock Forecast & Price Target GBX 1,802 +8.00 (+0.45%) As of 06:17 AM Eastern Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock Hikma Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 4 Analyst RatingsSell0Hold1Buy3 Based on 4 Wall Street analysts who have issued ratings for Hikma Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for HIK. Consensus Price Target GBX 2,436.67 According to the 4 analysts' twelve-month price targets for Hikma Pharmaceuticals, the average price target is GBX 2,436.67. The highest price target for HIK is GBX 2,750, while the lowest price target for HIK is GBX 2,000. The average price target represents a forecasted upside of 35.22% from the current price of GBX 1,802. Get the Latest News and Ratings for HIK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Hikma Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up HIK Analyst Ratings Over TimeTypeCurrent Forecast4/8/24 to 4/8/251 Month Ago3/9/24 to 3/9/253 Months Ago1/9/24 to 1/8/251 Year Ago4/9/23 to 4/8/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)2 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price TargetGBX 2,436.67GBX 2,436.67GBX 2,383.33GBX 2,068.75Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Remove Ads HIK Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History HIK Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Hikma Pharmaceuticals Stock vs. The CompetitionTypeHikma PharmaceuticalsMedical CompaniesConsensus Rating Score 2.75 2.82Consensus RatingModerate BuyModerate BuyNews Sentiment RatingNeutral NewsSee Recent HIK NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/10/2025Berenberg Bank2 of 5 stars Reiterated RatingBuyGBX 2,560+23.43%3/7/2025JPMorgan Chase & Co.2 of 5 stars Reiterated RatingOverweight6/18/2024Deutsche Bank Aktiengesellschaft3 of 5 stars Reiterated RatingBuyGBX 2,750+38.05%5/7/2024BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingEqual WeightGBX 2,000+1.47%11/13/2023Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingSector PerformGBX 2,150+22.16%10/3/2023CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy5/22/2023Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuyGBX 2,080 ➝ GBX 2,125+15.46%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:43 AM ET. HIK Forecast - Frequently Asked Questions What is Hikma Pharmaceuticals' forecast for 2025? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Hikma Pharmaceuticals is GBX 2,436.67, with a high forecast of GBX 2,750 and a low forecast of GBX 2,000. Should I buy or sell Hikma Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIK shares. Does Hikma Pharmaceuticals's stock price have much upside? According to analysts, Hikma Pharmaceuticals's stock has a predicted upside of 35.22% based on their 12-month stock forecasts. What analysts cover Hikma Pharmaceuticals? Hikma Pharmaceuticals has been rated by research analysts at Berenberg Bank, and JPMorgan Chase & Co. in the past 90 days. Do Wall Street analysts like Hikma Pharmaceuticals more than its competitors? Analysts like Hikma Pharmaceuticals less than other "medical" companies. The consensus rating score for Hikma Pharmaceuticals is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how HIK compares to other companies. Stock Forecasts and Research Tools Related Companies INDV Stock Forecast APH Stock Forecast EAH Stock Forecast HLN Stock Forecast SN Stock Forecast CTEC Stock Forecast GNS Stock Forecast ONT Stock Forecast CRW Stock Forecast SPI Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (LON:HIK) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredThese obscure companies are Trump’s favorites?Ten investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
